Stopped: Sponsor Decision - Not Safety Related
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Adverse Events
Timeframe: From first dose of study drug until 4 weeks following last dose of study drug (up to 16 weeks).
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)
Timeframe: Baseline up to Week 12
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Timeframe: Baseline up to Week 12
Number of Participants With Clinically Significant Changes in Vital Sign Measurements
Timeframe: Baseline up to Week 12
Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results
Timeframe: Baseline to Week 12
Number of Participants With Clinically Significant Findings in Suicidality Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)
Timeframe: Baseline to Week 12